Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CPT1b is a mitochondrial enzyme that catalyzes the transfer of long-chain fatty acyl groups from coenzyme A to L-carnitine, forming acylcarnitines. This reaction is essential for the transport of long-chain fatty acids from the cytoplasm into mitochondria for β-oxidation and energy production. CPT1b is considered a rate-limiting step in mitochondrial fatty acid oxidation (FAO), especially in tissues with high energy demands such as heart and skeletal muscle. Deficiency or inhibition of CPT1 can impair mitochondrial FAO, leading to hypoketotic hypoglycemia during fasting or illness due to inability to utilize fats for energy. It has also been explored as a target for metabolic therapies aimed at treating cardiac hypertrophy and heart failure, but safety concerns exist.
Inhibition of CPT1b reduces fatty acid oxidation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carnitine palmitoyltransferase 1B (CPT1b).